
Ascidian Therapeutics
NEWS
Ascidian Therapeutics, a member of BioSpace’s NextGen Class of 2024, on Monday announced it received IND clearance from the FDA and was granted Fast Track designation for ACDN-01.
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
IN THE PRESS
JOBS